SOUTH SAN FRANCISCO, Calif., Aug. 21, 2008 (GLOBE NEWSWIRE) -- Theravance, Inc. (Nasdaq:THRX) announced today that Rick E Winningham, Theravance's Chief Executive Officer, is scheduled to present at the Thomas Weisel Partners Healthcare Conference on Thursday, September 4, 2008, at 10:55 a.m. EDT. The conference will be held from September 3-5, 2008 at the Four Seasons, Boston, Massachusetts.
The presentation will be webcast live and can be reached from Theravance's web site at www.theravance.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc., the Horizon program and the bifunctional muscarinic antagonist-beta2 agonist (MABA) program with GlaxoSmithKline plc, and the Gastrointestinal Motility Dysfunction program. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com.
The Theravance, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3908
THERAVANCE(r), the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE(r) are registered trademarks of Theravance, Inc.
Theravance's presentation at the Thomas Weisel Partners Healthcare Conference will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives and future events. Theravance intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act and the Private Securities Litigation Reform Act of 1995.
